MX2012001908A - Metodo para reparar la neurodegeneracion. - Google Patents

Metodo para reparar la neurodegeneracion.

Info

Publication number
MX2012001908A
MX2012001908A MX2012001908A MX2012001908A MX2012001908A MX 2012001908 A MX2012001908 A MX 2012001908A MX 2012001908 A MX2012001908 A MX 2012001908A MX 2012001908 A MX2012001908 A MX 2012001908A MX 2012001908 A MX2012001908 A MX 2012001908A
Authority
MX
Mexico
Prior art keywords
neurodegeneration
repairing
afgf
subject
growth factor
Prior art date
Application number
MX2012001908A
Other languages
English (en)
Inventor
Henrich Cheng
Ming-Jei-Lo
Liu Yee-Chiang
Original Assignee
Eu Sol Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eu Sol Biotech Co Ltd filed Critical Eu Sol Biotech Co Ltd
Publication of MX2012001908A publication Critical patent/MX2012001908A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona un método para tratar la neurodegeneración provocada por el síndrome de compresión de nervios o neuropatía de atrapamiento, el cual comprende administrar el factor de crecimiento de fibroblastos ácidos humanos (aFGF) en un paciente con necesidad del mismo.
MX2012001908A 2009-08-14 2010-08-16 Metodo para reparar la neurodegeneracion. MX2012001908A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23398709P 2009-08-14 2009-08-14
PCT/CN2010/001240 WO2011017915A1 (en) 2009-08-14 2010-08-16 Method for repairing neurodegeneration

Publications (1)

Publication Number Publication Date
MX2012001908A true MX2012001908A (es) 2012-03-16

Family

ID=43585895

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012001908A MX2012001908A (es) 2009-08-14 2010-08-16 Metodo para reparar la neurodegeneracion.

Country Status (13)

Country Link
US (2) US9198953B2 (es)
EP (1) EP2464376B1 (es)
JP (1) JP2013501736A (es)
KR (1) KR20120051605A (es)
CN (1) CN102497876A (es)
AU (1) AU2010282105B9 (es)
BR (1) BRPI1016038A2 (es)
CA (1) CA2765265A1 (es)
IL (1) IL215986A0 (es)
MX (1) MX2012001908A (es)
NZ (1) NZ596075A (es)
TW (1) TWI434698B (es)
WO (1) WO2011017915A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110280838A1 (en) * 2007-12-27 2011-11-17 Advanced Technologies And Regenerative Medicine, Llc Treatment of intervertebral disc degeneration using human umbilical cord tissue-derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
TWI634898B (zh) * 2013-10-07 2018-09-11 雅祥生技醫藥股份有限公司 經修飾之人類酸性纖維母細胞生長因子及其組合物
JP2017508004A (ja) * 2014-02-18 2017-03-23 エイブラムソーン， グレン 麻痺を伴わない疼痛緩和のための組成物および方法
WO2019085872A1 (en) * 2017-10-31 2019-05-09 Eusol Biotech Co., Ltd. Use of afgf for preventing or treating diseases related to muscle wasting
EP3931211A4 (en) * 2019-02-28 2022-12-07 Eusol Biotech Co., Ltd. USE OF RECOMBINANT PROTEIN FOR TREATING METABOLIC DISORDERS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008828A1 (en) 1991-11-08 1993-05-13 Syntex-Synergen Neuroscience Joint Venture Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
WO1996022115A1 (en) * 1995-01-16 1996-07-25 Baxter International Inc. Self-supporting sheet-like material of cross-linked fibrin for preventing post operative adhesions
AU2001288256B2 (en) 2000-08-15 2006-03-30 New Technologies Holdings Pte Ltd A method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis
ES2284677T3 (es) 2000-08-15 2007-11-16 Phage Biotechnology Corporation Superproduccion de proteinas y peptidos biologicamente activos dependiente de fago.
US8146602B2 (en) * 2003-01-29 2012-04-03 Taipei Veterans General Hospital Method and mixture for nerve root repair
JP4505631B2 (ja) * 2004-03-31 2010-07-21 独立行政法人産業技術総合研究所 ヘパラン硫酸糖鎖を付加したヘパリン結合性タンパク質、その製造方法及びそれを含有する医薬組成物
US20070134204A1 (en) * 2005-12-09 2007-06-14 Henrich Cheng Method for treating nerve injury and vector construct for the same
WO2007138236A1 (en) * 2006-05-24 2007-12-06 The University Of Birmingham Sheddase enzymes for neuron growth
US20080109035A1 (en) * 2006-10-31 2008-05-08 Henrich Cheng Methods and Compositions for Repairing Common Peroneal Nerve Lesions
TWI363761B (en) * 2008-06-10 2012-05-11 Eu Sol Biotech Co Ltd Modified peptide of human acidic fibroblast growth factor

Also Published As

Publication number Publication date
JP2013501736A (ja) 2013-01-17
TW201124154A (en) 2011-07-16
WO2011017915A1 (en) 2011-02-17
IL215986A0 (en) 2012-01-31
EP2464376A4 (en) 2013-02-27
BRPI1016038A2 (pt) 2016-07-05
TWI434698B (zh) 2014-04-21
KR20120051605A (ko) 2012-05-22
AU2010282105B9 (en) 2015-07-30
EP2464376B1 (en) 2016-10-05
EP2464376A1 (en) 2012-06-20
AU2010282105A1 (en) 2011-11-10
CA2765265A1 (en) 2011-02-17
US20160106811A1 (en) 2016-04-21
AU2010282105B2 (en) 2015-07-23
US9198953B2 (en) 2015-12-01
CN102497876A (zh) 2012-06-13
NZ596075A (en) 2013-06-28
US20110039774A1 (en) 2011-02-17

Similar Documents

Publication Publication Date Title
WO2009129246A3 (en) Compositions and methods for preparing and using same
MY173616A (en) Compositions and methods for lowering triglycerides
MX2012001908A (es) Metodo para reparar la neurodegeneracion.
EP2305995A4 (en) Process for producing common rail, and common rail
AP2012006135A0 (en) Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof.
AP2011005760A0 (en) Tobacco curing method.
ZA201005090B (en) Carbon aerogels, process for their preparation and their use
MY149028A (en) Nalmefene hydrochloride dihydrate
MX2014013676A (es) Uso de moleculas de enlace a la semaforina-4d para promover la neurogenesis despues de la apoplejia.
FR2954773B1 (fr) Polyamide semi-aromatique, son procede de preparation, composition comprenant un tel polyamide et leurs utilisations
EP2374888A4 (en) PROCESS FOR PRODUCING RECOMBINANT HUMAN INSULIN
SG191060A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
FI20105758A (fi) Särmäyspuristin, särmäyspuristimen palkki ja pöytä, sekä menetelmä särmäyksessä
MX2011006721A (es) Formulacion farmaceutica de fenofibrato nanonizado.
GB201103780D0 (en) Treatment for ige-mediated disease
AU2012240388A8 (en) Treatment regimens
PL2300024T3 (pl) Sposób zmniejszania burczenia brzucha przez podawanie bakterii Bifidobacterium
WO2012004416A3 (en) Treatment of a disease associated with retinal degenerative disorder
UA42465U (ru) Способ профилактики лучевой болезни в эксперименте
MY151244A (en) A gene encoding a protein having an ability to enhance a selenate reduction activity
TN2010000463A1 (en) Compositions and methods for preparing and using same
UA88561C2 (ru) Способ получения антигемолитического препарата
UA33211U (ru) Способ лечения больных с синдромом повышенной усталости на фоне хронической патологии гепатобилиарной системы
UA49062U (ru) Способ лечения больных с синдромом повышенной утомляемости в сочетании с хронической патологией гепатобилиарной| системы
UA41375U (uk) Спосіб приготування комплексного рослинного препарату з седативною та загальнозміцнюючою дією

Legal Events

Date Code Title Description
FA Abandonment or withdrawal